GSK stock: Dividend yield for GSK stock stands at 4.00 percent

Published on 10/19/2026 at 15:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RBC kept GBp 1,975 on October 13, 2026. GSK stock costs EUR 21.99 on October 19, 2026, minus 0.36 percent versus the Xetra close.

Income and market measures

RBC Capital Markets kept a GBp 1,975 target on October 13, 2026.
GSK's market capitalization was USD 99.2 billion on October 16, 2026.
GSK stock costs EUR 21.99 at Lang & Schwarz on October 19, 2026 at 3:10 p.m. CEST, minus 0.36 percent versus the Xetra close of October 16, 2026.
GSK is scheduled to report results on October 28, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK's dividend yield stood at 4.00 percent on October 16, 2026, while RBC Capital Markets kept its Sector Perform rating and GBp 1,975 target on October 13, 2026, according to The Market Reporter. At Lang & Schwarz, GSK stock was trading at EUR 21.99 on October 19, 2026 at 3:10 p.m. CEST, minus 0.36 percent versus the Xetra close of October 16, 2026 at EUR 22.07.

Dividend yield and analyst target

The income profile remains a central part of the valuation picture. The indicated dividend yield was 4.00 percent as of October 16, 2026, based on the quoted market value. RBC's GBp 1,975 target and Sector Perform rating were dated October 13, 2026, ahead of the company's next scheduled results.

Price position on October 19

The euro quote was EUR 21.99, with a bid of EUR 21.97 and an ask of EUR 22.00 at 3:10 p.m. CEST. The Xetra comparison puts the stock EUR 0.08 below the October 16, 2026 close, equivalent to minus 0.36 percent. In the primary market, GSK last traded at USD 49.51 on October 16, 2026 at 4:00 p.m. ET, while its 52-week range was USD 42.85 to USD 61.70.

Valuation and October 28

GSK's market capitalization was USD 99.2 billion, its price-to-earnings ratio was 15.58, and average volume was 4,149,645 shares as of October 16, 2026. Yahoo Finance reported that GSK is scheduled to publish third-quarter results on October 28, 2026.

Comparison with peers

GSK: minus 0.36 percent, P/E 15.58, market capitalization USD 99.2 billion
AstraZeneca (Nasdaq, USD): minus 0.76 percent, P/E 24.61, market capitalization USD 256.5 billion
Pfizer (NYSE, USD): plus 0.48 percent, P/E 39.09, market capitalization USD 168.6 billion

Price and investor perspective

For investors, the contrast is between a 4.00 percent dividend yield and a share price sitting below the latest Xetra close. RBC's 1,975-pence target provides a dated external valuation reference, while the October 28 reporting date is the next scheduled company milestone.

GSK was trading at EUR 21.99 at Lang & Schwarz on October 19, 2026 at 3:10 p.m. CEST, minus 0.36 percent versus the Xetra close of October 16, 2026 at EUR 22.07. The further course of trading is shown by the continuously updated real-time quote of GSK stock.